An observational study in Cardiac Amyloidosis, sponsored by Central Hospital, Nancy, France. Completed at 1 site in France. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, and was the 34th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in France, United States, Argentina and 21 more countries
Ages 18–75
Gérond'if · Sites in France
Ages 80+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is below the median of 233 across 92 observational studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 128 across the 23 interventional studies, 175 across the 12 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Central Hospital, Nancy, France has 2 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
5 of the studies in Amyloid Neuropathies, Familial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103943Centre Hospitalier Régional d'OrléansAmyloidosis TTR Flow Reserve Evaluation | 2026-12-11 |
| NCT04849754GCS Ramsay Santé pour l'Enseignement et la RechercheAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy | 2026-12-31 |
| NCT04535349University Hospital, CaenQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis | 2027-06-15 |
| NCT05101304Saving Lives MattersRegistre HEAR, Healthcare European Amyloidosis Registry | 2027-06-30 |
| NCT06427304Gérond'ifCardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure | 2027-07-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.
Transthyretin cardiac amyloidosis (ATTR-CA) has emerged as a major cause of infiltrative cardiomyopathy, and early diagnosis is associated with improved prognosis. ATTR is now recognized far more frequently than in the past, owing to increased clinical awareness and advances in non-invasive imaging strategies, including planar bone scintigraphy.
In the absence of monoclonal gammopathy, a Perugini grade ≥ 2 on planar bone scintigraphy constitutes a highly specific diagnostic criterion for ATTR-CA, obviating in most cases the need for endomyocardial biopsy. Consequently, planar bone scintigraphy acquired with conventional Anger cameras has become the reference method in this setting.
In recent years, full-ring cadmium-zinc-telluride (CZT) single-photon emission computed tomography (SPECT) whole-body cameras have rapidly emerged. These systems offer enhanced image quality and count sensitivity, mainly due to the high intrinsic detection efficiency of CZT detectors and a dedicated full-ring geometry that optimizes photon collection over the patient's body or specific organs of interest. They have enabled the development of ultrafast three-dimensional acquisitions combined with SUV-based image scaling, thereby improving patient comfort and throughput, while also allowing lesion quantification.
However, the ability of rapid CZT-SPECT/CT acquisitions to accurately replicate the ATTR-CA diagnostic information obtained from standard planar imaging remains insufficiently documented. Furthermore, although CZT-SPECT/CT technology allows for precise quantification, it has not yet been established whether Standard Uptake Value (SUV) based parameters can serve as reliable and reproducible imaging biomarkers for ATTR-CA Therefore, the aim of this retrospective study will be to (i) evaluate whether fast CZT-SPECT recordings can reproduce the diagnosis of ATTR-CA obtained using Perugini scoring on standard planar images, either by applying Perugini scoring to planar projections or by using quantitative parameters, and (ii) compare the reproducibility of these approaches.
Retrospectively enrolled patients routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) . During this period, a rapid three-dimensional CZT-SPECT cardiac acquisition was systematically attempted in addition to conventional planar imaging, depending on camera availability, for diagnostic purposes, particularly for identifying blood-pool activity and other extracardiac confounding uptake areas
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients referred for bone scintigraphy for suspected ATTR-CA underwent a fast cardiac CZT-SPECT acquisition followed by standard whole-body planar imaging three or four hours after 99mTc-HMDP injection
Other: bone scintigraphy
Fast CZT camera bone scintigraphy and bone scintigraphy with conventional camera (standard care)
to evaluate whether fast CZT-SPECT recordings can reproduce the diagnosis of ATTR-CA obtained using Perugini scoring on standard planar images, either by applying Perugini scoring to planar projections or by using quantitative parameters
Comparison between Perugini score obtained on the bone scan scintigraphy performed with CZT SPECT and performed with conventional camera
Time frame: one day
Ran from Jun 2026 to primary completion in Jul 2026, 1 month.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start May 2026 → Jun 2026, primary completion Jun 2026 → Jul 2026 and completion Jul 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →
Central Hospital, Nancy, France →